Myeloproliferative Neoplasms

Jorge E. Cortes, MD, discusses the utility of ruxolitinib in myeloproliferative neoplasms.

Jacqueline S. Garcia, MD, discusses unmet needs for patients with myelofibrosis who progress on JAK inhibitors.

Tania Jain, MBBS, discusses the role of allogeneic stem cell transplant in myelofibrosis.

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the design and safety analysis of a phase II trial of luspatercept in patients with myelofibrosis-associated anemia.

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Prithviraj Bose, MD, discusses the high unmet need in post-myeloproliferative neoplasms acute myeloid leukemia and the impact of findings from the phase I/II trial on current and future treatment strategies in the space.

Haploidentical allogeneic stem cell transplant is a viable treatment option for patients with myelofibrosis who have a higher risk for posttransplant complications and mortality.

Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.

Srikanth Nagalla, MD, discusses the challenges of managing thrombocytopenia in patients with myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, discusses the differences between ruxolitinib and fedratinib in the treatment of patients with myeloproliferative neoplasms.

Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR, discusses the findings of the retrospective analysis of pulmonary hypertension in patients with myelofibrosis and their impact on clinical practice.

Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.

Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.

Shella Saint Fleur-Lominy, MD, PhD, discusses the effects ruxolitinib has on symptom burden in patients with myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, discusses some of the current and investigational treatment options for patients with myeloproliferative neoplasms.

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the state of treatment in myeloproliferative neoplasms (MPNs).

Mark A. Schroeder, MD, discusses therapies currently available and being investigated to treat patients with graft-versus-host disease.

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Naveen Pemmaraju, MD, discusses methods to address anemia in patients with myelodysplastic syndromes.

Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.

David S. Snyder, MD, discusses updates in treating patients with myelofibrosis who undergo transplant.

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

Jacqueline S. Garcia, MD, discusses the tolerability of the combination of navitoclax plus ruxolitinib in patients with myelofibrosis.

Aaron Gerds, MD, discusses results of a phase II trial examining the safety and efficacy of luspatercept as a treatment for anemia in patients with myelofibrosis.